The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.

But not every company with momentum is a long-term winner, and plenty of investors have lost money betting on short-term fads. On that note, here are three overhyped stocks that may correct and some you should consider instead.

Hyatt Hotels (H)

One-Month Return: -1.2%

Founded in 1957, Hyatt Hotels (NYSE: H) is a global hospitality company with a portfolio of 20 premier brands and over 950 properties across 65 countries.

Why Do We Think H Will Underperform?

1. Revenue per room has disappointed over the past two years due to weaker trends in its daily rates and occupancy levels
2. Operating margin of 4.8% falls short of the industry average, and the smaller profit dollars make it harder to react to unexpected market developments
3. Ability to fund investments or reward shareholders with increased buybacks or dividends is restricted by its weak free cash flow margin of 5.1% for the last two years

At $164.33 per share, Hyatt Hotels trades at 51.2x forward P/E. Dive into our free research report to see why there are better opportunities than H.

Sphere Entertainment (SPHR)

One-Month Return: +14.8%

Famous for its viral Las Vegas Sphere venue, Sphere Entertainment (NYSE: SPHR) hosts live entertainment events and distributes content across various media platforms.

Why Do We Pass on SPHR?

1. Muted 8.5% annual revenue growth over the last five years shows its demand lagged behind its consumer discretionary peers
2. Low free cash flow margin of 1.9% for the last two years gives it little breathing room, constraining its ability to self-fund growth or return capital to shareholders
3. Improving returns on capital suggest management is identifying more profitable investments

Sphere Entertainment’s stock price of $93.91 implies a valuation ratio of 14.1x forward EV-to-EBITDA. To fully understand why you should be careful with SPHR, check out our full research report (it’s free for active Edge members).

Elanco (ELAN)

One-Month Return: -5.2%

Originally established as a division of pharmaceutical giant Eli Lilly before becoming independent in 2018, Elanco Animal Health (NYSE: ELAN) develops and sells medications, vaccines, and other health products for pets and farm animals across more than 90 countries.

Why Is ELAN Not Exciting?

1. Sales trends were unexciting over the last two years as its 2.5% annual growth was below the typical healthcare company
2. Constant currency revenue growth has disappointed over the past two years and shows demand was soft
3. Negative returns on capital show management lost money while trying to expand the business

Elanco is trading at $22.21 per share, or 23.2x forward P/E. If you’re considering ELAN for your portfolio, see our FREE research report to learn more.

Stocks We Like More

Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.

The names generating the next wave of massive growth are right here in our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today.